Market-Changing Launches Expected In 2020
7 Product Launches To Watch Out For
We might only be halfway through 2019, but In Vivo is taking in the long view and exploring some of the market-altering new drugs on the horizon that are expected to win approval and experience first launches at the opening of the next decade.
You may also be interested in...
Farxiga, with a new indication to prevent hospitalization for heart failure in type 2 diabetes patients, is the first drug among the SGLT2 class to gain this indication outside of diabetics with renal disease.
Lack of significant reduction on cardiovascular deaths or a composite of major events may have been due to enrollment of a healthier population relative to other studies, said investigators from the DECLARE-TIMI 58 outcomes study, which was reported at the AHA meeting.
It is time for In Vivo's 12th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.